Arbaclofen
- Generic Name
- Arbaclofen
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClNO2
- CAS Number
- 69308-37-8
- Unique Ingredient Identifier
- NYU6UTW25B
- Background
Arbaclofen, or STX209, is the R-enantiomer of baclofen. It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind, placebo controlled trials. It has also been investigated as a treatment for spasticity due to multi...
- Indication
Investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01288716
- Locations
- 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States
🇺🇸Pharmax Research Clinic, Miami, Florida, United States
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT01282268
- Locations
- 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States
An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01064973
- Locations
- 🇺🇸
Southwest Autism Research & Resource Center, Phoenix, Arizona, United States
🇺🇸Red Oaks Psychiatry Associates, P.A., Houston, Texas, United States
🇺🇸Yale Child Study Center, New Haven, Connecticut, United States
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT01013480
- Locations
- 🇺🇸
University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States
🇺🇸M.I.N.D. Institute, Sacramento, California, United States
🇺🇸Red Oaks Psychiatry Associates, PA, Houston, Texas, United States
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00846547
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States
🇺🇸Red Oaks Psychiatry Associates, PA, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.